Lysosomal β-Galactosidase and β-Hexosaminidase Activities Correlate with Clinical Stages of Dementia Associated with Alzheimer's Disease and Type 2 Diabetes Mellitus
The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Multiple epidemiological studies have shown that individuals affected by type-2 diabetes mellitus (T2DM) carry a 2-to-5-fold higher risk of developing Alzheimer's disease (AD) when compared to non-diabetic subjects. Thus, biochemical parameters that can be easily and routinely assessed for high-confidence evaluation of diabetic conditions leading to AD (AD-T2DM) are regarded as efficient tools aimed at early diagnosis and, in turn, timely AD treatment. In this regard, the activity of lysosomal glycohydrolases may of use, in light of the implication of these enzymes in early events that underlie AD pathology and an overt correlation, in diabetes, between altered metabolic homeostasis, abnormal glycohydrolase secretion in body fluids, and occurrence of diabetic complications. Based on marked up-regulation previously shown in a peripheral, cell-based model of AD, we selected β-Galactosidase, β-Hexosaminidase, and α-Mannosidase to discriminate T2DM from AD-T2DM subjects. A screen of 109, 114, and 116 patients with T2DM, AD and AD-T2DM, respectively, was performed by testing enzyme activities in both blood plasma and peripheral blood mononuclear cells. Compared to age-matched, healthy controls (n = 122), β-Galactosidase and β-Hexosaminidase activities markedly diverged across the three groups, whereas virtually unchanged values were observed for α-Mannosidase. In particular, plasma β-Galactosidase and β-Hexosaminidase levels were higher in patients with AD-T2DM compared to those w…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Increased level of SA-β-Gal was also found in plasma samples from AD patients, compared to controls [184,185].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [185]
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine
Zweig, M. H., & Campbell, G. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.4.561 · Cited by 6,569
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
Pathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
A Century of Alzheimer's Disease
Goedert, M., & Spillantini, M. G. (2006) · Science · doi:10.1126/science.1132814 · Cited by 2,098
GSK-3: tricks of the trade for a multi-tasking kinase
Doble, B. W., & Woodgett, J. R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00384 · Cited by 2,084
Morris, J. C. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004870 · Cited by 1,641
Goldgaber, D., Lerman, M. I., McBride, O. W., Saffiotti, U., & Gajdusek, D. C. (1987) · Science · doi:10.1126/science.3810169 · Cited by 1,333
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048 · cited 3×
“Interestingly, levels of pro-inflammatory cytokines are more abundant in AD patients with CDR1 and CDR2, as compared to CDR3 patients suffering major cognitive declines [11, 61].”
BackgroundIncreased Risk of Type 2 Diabetes in Alzheimer Disease
Janson, J., Laedtke, T., Parisi, J. E., O’Brien, P., Petersen, R. C., & Butler, P. C. (2004) · Diabetes · doi:10.2337/diabetes.53.2.474 · Cited by 950 · cited 1×
“In this regard, it was reported that approximately 80% of AD patients had T2DM or showed abnormal blood glucose levels [27].”
BackgroundAggregation of vascular risk factors and risk of incident Alzheimer disease
Luchsinger, J. A., Reitz, C., Honig, L. S., Tang, M. X., Shea, S., & Mayeux, R. (2005) · Neurology · doi:10.1212/01.wnl.0000172914.08967.dc · Cited by 790
Cataldo, A. M., Peterhoff, C. M., Troncoso, J. C., Gomez-Isla, T., Hyman, B. T., & Nixon, R. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64538-5 · Cited by 776
A century-old debate on protein aggregation and neurodegeneration enters the clinic
Lansbury, P. T., & Lashuel, H. A. (2006) · Nature · doi:10.1038/nature05290 · Cited by 687
Rowe, C. C., Ackerman, U., Browne, W., Mulligan, R., Pike, K. L., O'Keefe, G., Tochon-Danguy, H., Chan, G., Berlangieri, S. U., Jones, G., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70001-2 · Cited by 671
Rai, A. J., Gelfand, C. A., Haywood, B. C., Warunek, D. J., Yi, J., Schuchard, M. D., Mehigh, R. J., Cockrill, S. L., Scott, G. B. I., Tammen, H., et al. (2005) · PROTEOMICS · doi:10.1002/pmic.200401245 · Cited by 545
QIU, W., & FOLSTEIN, M. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.01.004 · Cited by 538
Strachan, M. W. J., Deary, I. J., Ewing, F. M. E., & Frier, B. M. (1997) · Diabetes Care · doi:10.2337/diacare.20.3.438 · Cited by 529 · cited 1×
“Recently, clinical studies have revealed that patients with type 2 Diabetes Mellitus (T2DM), a heterogeneous metabolic disorder of glucose metabolism [13], are especially susceptible to AD [14–19], thereby pointing to T2DM as a likely risk factor [20–26].”
BackgroundHow does diabetes accelerate Alzheimer disease pathology?
Sims-Robinson, C., Kim, B., Rosko, A., & Feldman, E. L. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.130 · Cited by 492 · cited 1×
“Recently, clinical studies have revealed that patients with type 2 Diabetes Mellitus (T2DM), a heterogeneous metabolic disorder of glucose metabolism [13], are especially susceptible to AD [14–19], thereby pointing to T2DM as a likely risk factor [20–26].”
Common pathological processes in Alzheimer disease and type 2 diabetes: A review
Li, L., & Hölscher, C. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.09.001 · Cited by 367
Neurodegenerative lysosomal disorders: A continuum from development to late age
Nixon, R. A., Yang, D.-S., & Lee, J.-H. (2008) · Autophagy · doi:10.4161/auto.6259 · Cited by 362
Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain.
Cataldo, A. M., & Nixon, R. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.10.3861 · Cited by 340
Zhao, W.-Q., & Townsend, M. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.10.014 · Cited by 291
Therapy insight, type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease
Haan, M. N. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0124 · Cited by 284 · cited 1×
“Recently, clinical studies have revealed that patients with type 2 Diabetes Mellitus (T2DM), a heterogeneous metabolic disorder of glucose metabolism [13], are especially susceptible to AD [14–19], thereby pointing to T2DM as a likely risk factor [20–26].”
BackgroundDiagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease
Patterson, C., Feightner, J. W., Garcia, A., Hsiung, G.-Y. R., MacKnight, C., & Sadovnick, A. D. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.070796 · Cited by 268
Insulin Resistance and Alzheimers Disease: Molecular Links & Clinical Implications
Neumann, K., Rojo, L., Navarrete, L., Farias, G., Reyes, P., & Maccioni, R. (2008) · Current Alzheimer Research · doi:10.2174/156720508785908919 · Cited by 236
Aβ polymerization through interaction with membrane gangliosides
Matsuzaki, K., Kato, K., & Yanagisawa, K. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.01.008 · Cited by 222
AddNeuroMed—The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease
Lovestone, S., Francis, P., Kloszewska, I., Mecocci, P., Simmons, A., Soininen, H., Spenger, C., Tsolaki, M., Vellas, B., Wahlund, L., et al. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05064.x · Cited by 211
Self-citationHook, V. Y. H., Kindy, M., & Hook, G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708362200 · Cited by 207
Fagundes Chaves, M. L., Camozzato, A. L., Godinho, C., Kochhann, R., Schuh, A., de Almeida, V. L., & Kaye, J. (2007) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31811ff2b4 · Cited by 186
Role of gangliosides in Alzheimer’s disease
Yanagisawa, K. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.01.018 · Cited by 180
Altered plasma cytokine levels in Alzheimer's disease: Correlation with the disease progression
Motta, M., Imbesi, R., Di Rosa, M., Stivala, F., & Malaguarnera, L. (2007) · Immunology Letters · doi:10.1016/j.imlet.2007.09.002 · Cited by 176
Alzheimer 100 – highlights in the history of Alzheimer research
Jellinger, K. A. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0578-3 · Cited by 163
Regulating Secretory Lysosomes
Holt, O. J., Gallo, F., & Griffiths, G. M. (2006) · The Journal of Biochemistry · doi:10.1093/jb/mvj126 · Cited by 142
GM1 ganglioside-mediated accumulation of amyloid β-protein on cell membranes
Wakabayashi, M., Okada, T., Kozutsumi, Y., & Matsuzaki, K. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.01.060 · Cited by 136
Pathogenic cascades in lysosomal disease—Why so complex?
Walkley, S. U. (2009) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-008-1040-5 · Cited by 136
Adamec, E., Mohan, P. S., Cataldo, A. M., Vonsattel, J. P., & Nixon, R. A. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00281-5 · Cited by 121
The neuronal endosomal-lysosomal system in Alzheimer's disease
Nixon, R. A., Mathews, P. M., & Cataldo, A. M. (2001) · Journal of Alzheimer's Disease · doi:10.3233/jad-2001-3114 · Cited by 111
Amyloid Beta: The Alternate Hypothesis
Lee, H.-G., Zhu, X., Nunomura, A., Perry, G., & Smith, M. (2006) · Current Alzheimer Research · doi:10.2174/156720506775697124 · Cited by 96
Schernthaner, G. (2010) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-010-0748-7 · Cited by 80
Barrier, L., Ingrand, S. S., Damjanac, M., Bilan, A. R., Hugon, J., & Page, G. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.08.002 · Cited by 76
Cataldo, A. M., Barnett, J. L., Mann, D. M. A., & Nixon, R. A. (1996) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199606000-00004 · Cited by 74
Cathepsin D expression is decreased in Alzheimer's disease fibroblasts
Urbanelli, L., Emiliani, C., Massini, C., Persichetti, E., Orlacchio, A., Pelicci, G., Sorbi, S., Hasilík, A., Bernardi, G., & Orlacchio, A. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.09.005 · Cited by 71
Self-citationUrinary enzymes and low-molecular-mass proteins as indicators of diabetic nephropathy.
Jung, K., Pergande, M., Schimke, E., Ratzmann, K. P., & Ilius, A. (1988) · Clinical Chemistry · doi:10.1093/clinchem/34.3.544 · Cited by 68
Neurochemical dementia diagnostics: State of the art and research perspectives
Lewczuk, P., & Wiltfang, J. (2008) · PROTEOMICS · doi:10.1002/pmic.200700703 · Cited by 62
MicroRNA Implications across Neurodevelopment and Neuropathology
Martino, S., di Girolamo, I., Orlacchio, A., Datti, A., & Orlacchio, A. (2009) · BioMed Research International · doi:10.1155/2009/654346 · Cited by 61
Self-citationWu, W., Wang, M., Sun, Z., Wang, X., Miao, J., & Zheng, Z. (2010) · Acta Diabetologica · doi:10.1007/s00592-010-0198-0 · Cited by 54
Martino, S., Tiribuzi, R., Tortori, A., Conti, D., Visigalli, I., Lattanzi, A., Biffi, A., Gritti, A., & Orlacchio, A. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.115873 · Cited by 50
Self-citationUp-regulation of Glycohydrolases in Alzheimer's Disease Fibroblasts Correlates with Ras Activation
Emiliani, C., Urbanelli, L., Racanicchi, L., Orlacchio, A., Pelicci, G., Sorbi, S., Bernardi, G., & Orlacchio, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303030200 · Cited by 48
Self-citationRNA Interference as a Tool for Alzheimers Disease Therapy
Orlacchio, A., Bernardi, G., Orlacchio, A., & Martino, S. (2007) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955707782331678 · Cited by 45
Self-citationPitk�nen, E., Kyll�stinen, M., Koivula, T., & Hormila, P. (1980) · Diabetologia · doi:10.1007/bf00251004 · Cited by 44
Martino, S., di Girolamo, I., Cavazzin, C., Tiribuzi, R., Galli, R., Rivaroli, A., Valsecchi, M., Sandhoff, K., Sonnino, S., Vescovi, A. L., et al. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05919.x · Cited by 38
Self-citationWeitgasser, R., Schnöll, F., Gappmayer, B., & Kartnig, I. (1999) · Diabetes Care · doi:10.2337/diacare.22.11.1882 · Cited by 33
Elevation of plasma β-amyloid level by glucose loading in Alzheimer mouse models
Takeda, S., Sato, N., Uchio‐Yamada, K., Sawada, K., Kunieda, T., Takeuchi, D., Kurinami, H., Shinohara, M., Rakugi, H., & Morishita, R. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.05.037 · Cited by 27
Smach, M. A., Charfeddine, B., Lammouchi, T., Harrabi, I., Othman, L. B., Dridi, H., Bennamou, S., & Limem, K. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.05.076 · Cited by 27
Ohyagi, Y., & Tabira, T. (2006) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955706778560175 · Cited by 25
Burlina, A., Goi, G., Fabi, A., Lombardo, A., Gaburro, D., & Tettamanti, G. (1987) · Clinical Biochemistry · doi:10.1016/0009-9120(87)90009-9 · Cited by 23
Waters, P. J., Flynn, M. D., Corrall, R. J. M., & Pennock, C. A. (1992) · Diabetologia · doi:10.1007/bf00401431 · Cited by 21
Plasma N-acetyl-?,D-glucosaminidase activities and glycaemia in diabetes mellitus
Poon, P. Y. W., Davis, T. M. E., Dornan, T., & Turner, R. C. (1983) · Diabetologia · doi:10.1007/bf00257342 · Cited by 19
Beccari, T., Mancuso, F., Costanzi, E., Tassi, C., Barone, R. M. E., Fiumara, A., Orlacchio, A., Aisa, M. C., & Orlacchio, A. (2000) · Clinica Chimica Acta · doi:10.1016/s0009-8981(00)00360-0 · Cited by 17
Self-citationSopelsa, A. M. I., Severini, M. H. A., Silva, C. M. D. D., Tobo, P. R., Giugliani, R., & Coelho, J. C. (2000) · Clinical Biochemistry · doi:10.1016/s0009-9120(00)00049-7 · Cited by 14
Yamamoto, N., Taniura, H., & Suzuki, K. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06620.x · Cited by 11
Maciejewski, R., Burski, K., Baj, J., Madej, B., Burdan, F., Dâbrowski, A., & Brakowiecki, F. (2001) · PubMed · Cited by 11
Hultberg, B. L., Isakgsson, A., Agardh, E., & Agardh, C. D. (1995) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365519509075402 · Cited by 7
Effects of Vitamin C on Fibroblasts from Sporadic Alzheimer’s Disease Patients
Costanzi, E., Martino, S., Persichetti, E., Tiribuzi, R., Massini, C., Bernardi, G., Orlacchio, A., & Orlacchio, A. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9539-y · Cited by 7
Self-citation
Cited by
Ageing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
“Increased level of SA-β-Gal was also found in plasma samples from AD patients, compared to controls [184,185].”
ResultCellular Senescence in Neurodegenerative Diseases
Martínez-Cué, C., & Rueda, N. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00016 · Cited by 281
“Increased levels of senescent cells with higher SA-β-gal and p53 levels are also found and in plasma samples from AD patients and mouse models of AD (de la Monte et al., 1997; Tiribuzi et al., 2011; Magini et al., 2015; Caldeira et al., 2017).”
BackgroundTiribuzi, R., Crispoltoni, L., Porcellati, S., Di Lullo, M., Florenzano, F., Pirro, M., Bagaglia, F., Kawarai, T., Zampolini, M., Orlacchio, A., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.08.003 · Cited by 162
Self-citationEndo‐lysosomal and autophagic dysfunction: a driving factor in Alzheimer's disease?
Whyte, L. S., Lau, A. A., Hemsley, K. M., Hopwood, J. J., & Sargeant, T. J. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.13935 · Cited by 150
“Conversely, the activity of these enzymes, as well as that of a-mannosidase, within peripheral blood mononuclear cells is decreased, indicating that there may be greater secretion of these lysosomal enzymes into the extracellular milieu (Tiribuzi et al. 2011).”
BackgroundAre there roles for brain cell senescence in aging and neurodegenerative disorders?
Tan, F. C. C., Hutchison, E. R., Eitan, E., & Mattson, M. P. (2014) · Biogerontology · doi:10.1007/s10522-014-9532-1 · Cited by 116
Metadata
- Authors
- Tiribuzi, R., Orlacchio, A., Crispoltoni, L., Maiotti, M., Zampolini, M., De Angeliz, M., Mecocci, P., Cecchetti, R., Bernardi, G., Datti, A., Martino, S., & Orlacchio, A.
- Affiliations
- University of Perugia (IT)
- University of Rome Tor Vergata (IT)
- Neuropsicologia Clinica, Ospedale S. Giovanni Battista, Foligno, Italy
- U.O. S.S. Ambulatoriale di Diabetologia Di.M.I., University of Perugia, Perugia, Italy
- Corresponding author
- Orlacchio, Aldo
- ORCID
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2011-05-30
- Volume
- 24
- Issue
- 4
- Pages
- 785-797
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1772878786
- Cited by
- 43
- References
- 0
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 1 · 2023: 4 · 2022: 2 · 2021: 2 · 2020: 6 · 2019: 3 · 2018: 2 · 2017: 3 · 2016: 4 · 2015: 3 · 2014: 3 · 2013: 3 · 2012: 1
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, type 2 diabetes
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, beta-Galactosidase, beta-N-Acetylhexosaminidases, Dementia, Diabetes Mellitus, Type 2, Enzyme Activation, Female, Humans, Lysosomes, Male, Biomarkers, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.